Association between body mass index, obesity, and vulvar cancer recurrence

IF 2.4 3区医学 Q2 OBSTETRICS & GYNECOLOGY International Journal of Gynecology & Obstetrics Pub Date : 2025-01-24 DOI:10.1002/ijgo.16182

Yossi Tzur, Angela Magri, Raanan Meyer, Melica Nourmoussavi Brodeur, Shannon Salvador, Susie Lau, Walter Gotlieb, Gabriel Levin

{"title":"Association between body mass index, obesity, and vulvar cancer recurrence","authors":"Yossi Tzur, Angela Magri, Raanan Meyer, Melica Nourmoussavi Brodeur, Shannon Salvador, Susie Lau, Walter Gotlieb, Gabriel Levin","doi":"10.1002/ijgo.16182","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>The objective of this paper is to study the association between obesity and tumor recurrence in patients with vulvar cancer.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This is a retrospective study including vulvar cancer patients from 2003 to 2022. Our primary outcome was progression-free survival (PFS) stratified by status of obesity, defined as body mass index (BMI) >30.0 kg/m<sup>2</sup>.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Overall, 48 patients were included in the study, with 32 (66.7%) diagnosed at early stages (I–II). The median BMI was 28.0 kg/m<sup>2</sup> [interquartile range 24.9–32.3 kg/m<sup>2</sup>]. There were 13 obese patients (27%), and the median follow-up time was 55 months [interquartile range 14–102]. Most patients (80%) were HPV-independent of human papilloma virus. Surgical intervention was the primary treatment modality for 88% (<i>n</i> = 42) of the cohort, and 26 patients (54%) received adjuvant chemoradiation. Disease recurrence was identified in 28 patients (58%). The median PFS was 68 months, and the median overall survival was 109 months. There was no difference in the median PFS between obese patients and non-obese patients (<i>P</i> = 0.370). In a Cox regression analysis, after adjusting for patient age, margin-free distance, and stage of disease, BMI was not associated with PFS hazard ratio 1.06 (0.99–1.12).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Obesity is not associated with PFS in patients with vulvar cancer, and BMI might not be considered a risk factor for recurrence.</p>\n </section>\n </div>","PeriodicalId":14164,"journal":{"name":"International Journal of Gynecology & Obstetrics","volume":"170 1","pages":"268-273"},"PeriodicalIF":2.4000,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ijgo.16182","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Gynecology & Obstetrics","FirstCategoryId":"3","ListUrlMain":"https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.16182","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

The objective of this paper is to study the association between obesity and tumor recurrence in patients with vulvar cancer.

Methods

This is a retrospective study including vulvar cancer patients from 2003 to 2022. Our primary outcome was progression-free survival (PFS) stratified by status of obesity, defined as body mass index (BMI) >30.0 kg/m².

Results

Overall, 48 patients were included in the study, with 32 (66.7%) diagnosed at early stages (I–II). The median BMI was 28.0 kg/m² [interquartile range 24.9–32.3 kg/m²]. There were 13 obese patients (27%), and the median follow-up time was 55 months [interquartile range 14–102]. Most patients (80%) were HPV-independent of human papilloma virus. Surgical intervention was the primary treatment modality for 88% (n = 42) of the cohort, and 26 patients (54%) received adjuvant chemoradiation. Disease recurrence was identified in 28 patients (58%). The median PFS was 68 months, and the median overall survival was 109 months. There was no difference in the median PFS between obese patients and non-obese patients (P = 0.370). In a Cox regression analysis, after adjusting for patient age, margin-free distance, and stage of disease, BMI was not associated with PFS hazard ratio 1.06 (0.99–1.12).

Conclusion

Obesity is not associated with PFS in patients with vulvar cancer, and BMI might not be considered a risk factor for recurrence.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

体重指数、肥胖和外阴癌复发之间的关系。

目的：探讨外阴癌患者肥胖与肿瘤复发的关系。方法：对2003 ~ 2022年外阴癌患者进行回顾性研究。我们的主要终点是按肥胖状态分层的无进展生存期（PFS），定义为体重指数（BMI） bb0 ~ 30.0 kg/m2。结果：总体而言，48例患者纳入研究，其中32例（66.7%）诊断为早期（I-II）。BMI中位数为28.0 kg/m2[四分位数间距24.9-32.3 kg/m2]。肥胖患者13例（27%），中位随访时间55个月[四分位数范围14-102]。大多数患者（80%）与人乳头瘤病毒无关。手术干预是88% （n = 42）患者的主要治疗方式，26例（54%）患者接受了辅助放化疗。28例（58%）患者出现疾病复发。中位PFS为68个月，中位总生存期为109个月。肥胖患者和非肥胖患者的中位PFS无差异（P = 0.370）。在Cox回归分析中，在调整患者年龄、无边缘距离和疾病分期后，BMI与PFS风险比1.06（0.99-1.12）无关。结论：肥胖与外阴癌患者的PFS无关，BMI可能不是复发的危险因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

International Journal of Gynecology & Obstetrics 医学-妇产科学

CiteScore

5.80

自引率

2.60%

发文量

493

审稿时长

3-6 weeks

期刊介绍： The International Journal of Gynecology & Obstetrics publishes articles on all aspects of basic and clinical research in the fields of obstetrics and gynecology and related subjects, with emphasis on matters of worldwide interest.